G protein-coupled receptor 40/free fatty acid receptor 1 (GPR40/ FFA 1 ) is highly expressed in pancreatic ␤ cells and mediates free fatty acid-induced insulin secretion. This study examined the pharmacological effects and potential for avoidance of lipotoxicity of [(3S)-6-({2Ј,6Ј-dimethyl-4Ј-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}meth-oxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemihydrate) (TAK-875), a novel, orally available, selective GPR40 agonist. Insulinoma cell lines and primary rat islets were used to assess the effects of TAK-875 in vitro. The in vivo effects of TAK-875 on postprandial hyperglycemia, fasting hyperglycemia, and normoglycemia were examined in type 2 diabetic and normal rats. In rat insulinoma INS-1 833/15 cells, TAK-875 increased intracellular inositol monophosphate and calcium concentration, consistent with activation of the Gq␣ signaling pathway. The insulinotropic action of TAK-875 (10 M) in INS-1 833/15 and primary rat islets was glucose-dependent. Prolonged exposure of cytokine-sensitive INS-1 832/13 to TAK-875 for 72 h at pharmacologically active concentrations did not alter glucose-stimulated insulin secretion, insulin content, or caspase 3/7 activity, whereas prolonged exposure to palmitic or oleic acid impaired ␤ cell function and survival. In an oral glucose tolerance test in type 2 diabetic N-STZ-1.5 rats, TAK-875 (1-10 mg/kg p.o.) showed a clear improvement in glucose tolerance and augmented insulin secretion. In addition, TAK-875 (10 mg/kg, p.o.) significantly augmented plasma insulin levels and reduced fasting hyperglycemia in male Zucker diabetic fatty rats, whereas in fasted normal Sprague-Dawley rats, TAK-875 neither enhanced insulin secretion nor caused hypoglycemia even at 30 mg/kg. TAK-875 enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia with a low risk of hypoglycemia and no evidence of ␤ cell toxicity.
Introduction
Insulin resistance and impaired insulin secretion are major causes of the onset and development of type 2 diabetes (Muoio and Newgard, 2008) . Drugs that enhance insulin secretion, such as sulfonylureas and meglitinides, are commonly used for the treatment of type 2 diabetes. However, these drugs enhance insulin secretion by direct closure of the K ATP channel independent of blood glucose levels, thereby causing hypoglycemia (Doyle and Egan, 2003) . Hence, patients with diabetes would benefit from the development of a novel antidiabetic drug that has a low hypoglycemic risk and effectively improves blood glucose control.
Secretion of insulin from pancreatic ␤ cells is stimulated by glucose and other nutrients, including free fatty acids (FFAs) (Prentki et al., 1997; Haber et al., 2003) . In isolated human and rodent islets, FFAs enhance insulin secretion in a manner that depends on glucose concentration (Gravena et al., 2002) . Plasma concentrations of FFAs are elevated in the fasted state, and they play a role in the enhancement of the postprandial insulin response in vivo (Stein et al., 1996; Dobbins et al., 1998) . GPR40, a G protein-coupled receptor highly expressed in pancreatic ␤ cells, has been identified as a receptor for both saturated and unsaturated medium-and long-chain FFAs (Briscoe et al., 2003; Itoh et al., 2003; Kotarsky et al., 2003) . In addition, Itoh et al. (2003) demonstrated that the suppression of GPR40/FFA 1 mRNA with small interfering RNA inhibited the enhancement of FFAinduced insulin secretion in mouse insulinoma MIN6 cells, indicating that GPR40/FFA 1 is involved in the stimulation of acute insulin secretion by FFAs. The role of GPR40/FFA 1 in insulin secretion has also been confirmed by the use of selective small-molecule GPR40/FFA 1 agonists (Briscoe et al., 2006; Tan et al., 2008) .
In pancreatic ␤ cells, elevation of intracellular calcium triggers insulin secretion (Prentki et al., 1997) . Generally, activation of Gq␣ protein-coupled receptors results in phospholipase C activation, inositol 1,4,5-triphosphate (IP 3 ) and diacylglycerol production, and increases in intracellular calcium concentration ([Ca 2ϩ ] i ) (Taylor et al., 1991) . Studies have shown that GPR40/FFA 1 is coupled mainly with Gq␣ in rodent ␤ cell lines, and agonist stimulation of GPR40/FFA 1 with FFAs enhances [Ca 2ϩ ] i and insulin secretion in these cells, which can be blocked by inhibitors of Gq␣ signaling (Fujiwara et al., 2005; Shapiro et al., 2005) .
Whereas FFAs acutely stimulate insulin secretion, chronic exposure to them causes ␤ cell dysfunction and/or cell death, so-called lipotoxicity (Haber et al., 2003; Morgan, 2009) . Because endogenous ligands of GPR40/FFA 1 are medium-and long-chain FFAs, it has been suggested that GPR40/FFA 1 might mediate chronic toxic effects of FFAs (Steneberg et al., 2005) . However, conflicting results obtained from GPR40/ FFA 1 -deficient mice have also been reported (Latour et al., 2007; Kebede et al., 2008; Lan et al., 2008; Alquier et al., 2009 ); these did not show the harmful effects of GPR40/FFA 1 in pancreatic ␤ cells. Moreover, Nagasumi et al. (2009) have reported that the overexpression of GPR40/FFA 1 in pancreatic ␤ cells of mice results in enhanced insulin secretion, improved glucose tolerance, and resistance to impairment of glucose tolerance induced by a high-fat diet. Therefore, it remains under debate whether GPR40/FFA 1 agonism or antagonism would be more favorable for the treatment of type 2 diabetes and related disorders.
[(3S)-6-({2Ј, 6Ј-dimethyl-4Ј-[3-(methylsulfonyl) propoxy]biphenyl-3-yl}meth-oxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemi-hydrate (TAK-875) was identified as a potent and selective small-molecule agonist for GPR40/FFA 1 , which exhibits rapid absorption, high C max , and high plasma exposure with high bioavailabilities in rats and dogs (Negoro et al., 2010) . TAK-875 was also well tolerated after the administration of a single oral dose in healthy volunteers and has pharmacokinetic characteristics suitable for a once-daily regimen (Naik et al., 2011) . The current study was conducted to evaluate the cellular signaling events induced by TAK-875 and the pharmacological effects in various in vitro and in vivo models and to determine whether TAK-875 affects ␤ cell function and survival via the prolonged activation of GPR40/FFA 1 , as has been observed with FFAs. Our results suggest that GPR40/FFA 1 does not mediate the chronic toxic effects of FFAs, and selective activation of GPR40/FFA 1 with TAK-875 enhances glucose-dependent insulin secretion in a manner consistent with activation of the Gq␣-mediated pathway without inducing ␤ cell toxicity.
Materials and Methods
Reagents. TAK-875 (Negoro et al., 2010) was synthesized in the Chemical Development Laboratories at Takeda Pharmaceutical Company Limited. TAK-875 was dissolved in dimethyl sulfoxide (DMSO), and oleic acid (Sigma, St. Louis, MO) was dissolved in 95% ethanol for in vitro experiments unless otherwise indicated. For the experiments of 72-h exposure in vitro, sodium palmitic acid (Chem Service, West Chester, PA) and sodium oleic acid (Sigma) were dissolved in hot distilled water and added to the equal volume of 20% (w/v) free fatty acid-free BSA (Wako Pure Chemicals, Osaka, Japan) solution with stirring on ice. TAK-875 dissolved in DMSO was added to 10% BSA solution. Final concentrations of BSA and DMSO in the experiments of subchronic treatment were 1 and 0.1%, respectively, in all samples.
Animals. The care and use of the animals and the experimental protocols used in this research were approved by the Experimental Animal Care and Use Committee of Takeda Pharmaceutical Company Limited, and standards from the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996) were maintained throughout the study. All rats were fed regular chow CE-2 (CLEA Japan, Tokyo, Japan) and tap water ad libitum with controlled temperature (23°C), humidity (55%), and lighting (lights on from 7:30 AM to 7:30 PM). Male N-STZ-1.5 rats were generated by subcutaneous injection of 120 mg/kg streptozotocin in male Wistar Kyoto rats 1 to 2 days after birth. Male SpragueDawley (SD) rats, male Zucker diabetic fatty (ZDF) rats, and their Zucker lean (ZL) littermates were obtained from Charles River Laboratories Japan, Inc. (Yokohama, Japan).
Cells. Chinese hamster ovary (CHO; dihydrofolate reductase negative) cells stably expressing human or rat GPR40/FFA 1 and control cells (CHO-mock) (Negoro et al., 2010) were cultured in ␣-minimum essential medium without nucleotide (Invitrogen, Carlsbad, CA) supplemented with 10% dialyzed and heat-inactivated FBS (Thermo Fisher Scientific, Scoresby, Australia), 100 IU/ml penicillin, and 100 g/ml streptomycin (Invitrogen). The cell lines 833/15 and 832/13, derived from INS-1 rat insulinoma cells, were obtained from Dr. Christopher B. Newgard (Duke University Medical Center, Durham, NC). Cells were grown in RPMI medium 1640 containing L-glutamine (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 10 mM HEPES (Invitrogen), 10% heat-inactivated FBS (Thermo Fisher Scientific), 55 M 2-mercaptoethanol (Invitrogen), 100 IU/ml penicillin, and 100 g/ml streptomycin. Cells were cultured in a humidified atmosphere containing 5% CO 2 /95% air at 37°C.
Measurement of Intracellular Inositol Phosphate Production. Intracellular inositol monophosphate (IP) measurements were carried out using an IP-One ELISA kit (Cisbio, Bedford, MA) according to the manufacturer's instruction. In brief, CHO cells or INS-1 833/15 cells were suspended in the culture medium described above and seeded at a density of 8 ϫ 10 4 and 5 ϫ 10 4 cells/well, respectively, in 96-well plates (Nalge Nunc International, Rochester, NY), and the cells were cultured overnight. After the medium was discarded, cells were incubated at 37°C for 1 h with stimulation buffer (146 mM NaCl, 4.2 mM KCl, 0.5 mM MgCl 2 , 1 mM CaCl 2 , 10 mM HEPES, 5.5 mM glucose, and 50 mM LiCl, pH 7.4) in the absence or presence of stimulators as shown. In the experiments using INS-1 833/15 cells, glucose at 1, 3, or 10 mM concentrations was added to the glucose-free stimulation buffer. After the incubation, lysis reagent was added, the plate was incubated for another 30 min at 37°C, and intracellular IP concentration was measured. EC 50 values were calculated by logistic regression analysis (SAS Institute, Cary, NC). jpet.aspetjournals.org methyl ester (Dojindo, Kumamoto, Japan) in Krebs-Ringer-bicarbonate HEPES buffer (KRBH) containing 0.025% pluronic F-127 (Invitrogen), 1 mM glucose, and 1% FBS (loading buffer), followed by washing with loading buffer without Fura-2 acetoxymethyl ester. After the washing, KRBH containing 1, 3, or 10 mM glucose and 0.1% DMSO was added, the cells were excited at 340 and 380 nm alternatively, the emission signals at 510 nm were detected every 10 s by a cooled charge-coupled device camera, and the ratio was derived using an AquaCosmos (Hamamatsu Photonics, Hamamatsu, Japan). After monitoring of the glucose-induced calcium response, the equivalent volume of KRBH containing glucose and test agents was added. The average of 340/380 fluorescence ratios was obtained from 30 randomly selected cells.
Acute Insulin Secretion Assay. INS-1 833/15 cells were seeded at a density of 5 ϫ 10 4 cells/well in a 96-well plate, and the cells were cultured in RPMI medium overnight before experiments. After discarding of the medium, the cells were preincubated for 2 h with KRBH containing 1 mM glucose. After discarding of the preincubation buffer, KRBH containing glucose and stimulators as indicated was added, and the plate was incubated for 2 h at 37°C. After incubation, supernatants from each well were collected, and secreted insulin concentration was measured using a rat insulin ELISA (Morinaga, Tokyo, Japan) according to the manufacturer's instruction.
Insulin Secretion and Intracellular Insulin Content after Prolonged Exposure. INS-1 832/13 cells were suspended in RPMI medium and seeded in a 96-well plate at a density of 2 ϫ 10 4 cells/well; 1% BSA and 0.1% DMSO alone (control), palmitic acid (10, 100, and 1000 M), oleic acid (10, 100, and 1000 M), or TAK-875 (1, 10, and 100 M) was added to the plate. After 72-h culture, medium was discarded, and cells were preincubated for 2 h with KRBH containing 1 mM glucose and 0.2% BSA at 37°C. After discarding of the preincubation buffer, KRBH containing 1 or 20 mM glucose and 0.2% BSA was added, and the plate was further incubated for 2 h. The insulin concentration in the supernatant was measured as described above. To measure intracellular insulin content, INS-1 832/13 cells were exposed to 1% BSA and 0.1% DMSO alone (control), palmitic acid (1000 M), oleic acid (1000 M), or TAK-875 (100 M) with 1% BSA and 0.1% DMSO, as described above. After incubation, cells were washed once with phosphate-buffered saline, and acidethanol solution was added to each well, followed by sonication on ice. Intracellular insulin was extracted by overnight incubation at Ϫ30°C, followed by separation of supernatant by centrifugation at 12,000 rpm ϫ 5 min at 4°C.
Measurement of Caspase 3/7 Activity. INS-1 832/13 cells were suspended in RPMI medium containing 11 mM glucose and the supplements described above. These cells were seeded at a density of 2 ϫ 10 4 cells/well in a 96-well black plate coated with poly-D-lysine (BD BioCoat), and 1% BSA and 0.1% DMSO alone (control), palmitic acid (62.5, 125, 250, 500, and 1000 M), oleic acid (62.5, 125, 250, 500, and 1000 M), or 12.5, 25, 50 , and 100 M) was added to the plate with 1% BSA and 0.1% DMSO, followed by culture for 72 h. After the culture, caspase 3/7 activity was measured with the Apo-one homogeneous caspase 3/7 assay (Promega, Madison, WI) according to the manufacturer's instructions. Fluorescence intensity was measured at an excitation of 485 nm and an emission at 535 nm.
Oral Glucose Tolerance Test and Effects on Fasting Normoglycemia and Hyperglycemia. At 18 weeks of age, the N-STZ-1.5 rats were fasted overnight and orally given vehicle (0.5% methylcellulose) or TAK-875 (1, 3, and 10 mg/kg). Sixty minutes later, all animals received an oral glucose load (1 g/kg). Blood samples were collected from the tail vein before drug administration, before glucose load (time 0), and 10, 30, 60, and 120 min after the glucose load. Plasma glucose and insulin levels were measured with an AutoAnalyzer 7080 (Hitachi, Yokohama, Japan) and radioimmunoassay (LINCO Research, St. Charles, MO), respectively. To see the effects of TAK-875 on fasting normoglycemia and hyperglycemia, SD rats (8 weeks old) or ZDF and ZL rats (12 weeks old) were fasted overnight and orally given vehicle (0.5% methylcellulose), TAK-875 (10 or 30 mg/kg), nateglinide (50 mg/kg), or glibenclamide (10 mg/kg). Blood samples were collected from the tail vein before drug administration (time 0) and 0.5, 1, 2, and 3 h (SD rats) and 0.5, 1, 2, 4, and 6 h (ZDF and ZL rats) after drug administration, and plasma glucose and insulin levels were measured as described above.
Statistics. Differences between two groups were analyzed by Student's t test or the Aspin-Welch test. For the multiple comparisons, differences versus control were tested by Dunnett's test or the Steel test. In the dose-dependent study, statistical significance versus control was assessed by the one-tailed Williams' test.
Results
Comparison of TAK-875 and Endogenous Ligand Agonist Activity for GPR40/FFA 1 . It has been demonstrated that TAK-875 increases [Ca 2ϩ ] i in CHO cells expressing the human or rat GPR40/FFA 1 (Negoro et al., 2010) , but the agonist activity has not been compared with that of endogenous ligands. Thus, we first compared the agonist activity of TAK-875 with that of an endogenous ligand, oleic acid, by measuring intracellular IP, a downstream metabolite of IP 3 , in CHO cells expressing human GPR40/FFA 1 (CHO-hGPR40). TAK-875 (0.01-10 M) produced a concentration-dependent increase in intracellular IP production in CHO-hGPR40 (Fig. 1A) . Oleic acid (3-100 M) also enhanced intracellular IP production in a concentration-dependent manner, but required much higher ligand concentrations to activate the receptor in comparison with TAK-875. EC 50 values for TAK-875 and oleic acid were 0.072 and 29.9 M, respectively, demonstrating that TAK-875 is Ͼ400-fold more potent at activating hGPR40 than oleic acid. Neither TAK-875 nor oleic acid elicited an IP response in control CHO cells devoid of hGPR40 (Fig. 1B) .
TAK-875 Activates the Gq␣-Mediated Signaling Pathway in Pancreatic ␤ Cells. We next examined whether TAK-875 activates the Gq␣-mediated signaling pathway in pancreatic ␤ cells as observed in CHO cells by measuring the ability of TAK-875 to stimulate IP production and increase [Ca 2ϩ ] i . Rat insulinoma INS-1 cell clone 833/15 was used as a pancreatic ␤ cell model. It has been reported that INS-1 cells express endogenous GPR40/FFA 1 (Schnell et al., 2007) . Prior studies confirmed that INS-1 833/15 cells highly expressed endogenous GPR40/FFA 1 mRNA to an extent similar to that observed in primary rat islets (data not shown). TAK-875 (0.1-10 M) dosedependently augmented intracellular IP production in these cells in the presence of 10 mM glucose, whereas one of the sulfonylurea drugs, glibenclamide, did not (Table 1) . Glucose concentration did not affect TAK-875-induced IP production, and almost equivalent TAK-875-induced IP production was observed in the presence of 1 and 3 mM glucose compared with 10 mM glucose.
As shown in Fig. 2A (Fig. 2, B-D) . We next examined the glucose dependence of these [Ca 2ϩ ] i elevations by TAK-875. As shown in Fig. 3 , the TAK-875 (30 M)-induced increase in [Ca 2ϩ ] i was attenuated at glucose concentrations of 1 and 3 mM, compared with the response observed in 10 mM glucose (Fig. 3, A-C) . In contrast, glibenclamide (10 M) augmented [Ca 2ϩ ] i independent of glucose concentrations (Fig. 3, D-F) . TAK-875 Augments Glucose-Dependent Insulin Secretion in Pancreatic ␤ Cells. The insulinotropic effects of TAK-875 in the presence of different concentrations of glucose were examined. As shown in Fig. 4A , in the presence of 10 mM glucose, TAK-875 (0.001-10 M) dose-dependently stimulated insulin secretion from INS-1 833/15 cells. TAK-875, at 10 M, enhanced insulin secretion 1.8-fold, compared with 10 mM glucose alone. Similar to the glucose concentration-dependent effects observed with intracellular calcium mobilization (Fig. 3, A-C) , TAK-875 significantly augmented insulin secretion from INS-1 833/15 cells in the presence of glucose at a concentration of 10 mM but not at 1 or 3 mM (Fig. 4B) . In contrast, glibenclamide-induced insulin secretions from these cells were independent of glucose concentration.
The effects of TAK-875 on glucose-induced insulin secretion were also evaluated in pancreatic islets isolated from normal Sprague-Dawley rats. TAK-875, at 10 M, significantly enhanced insulin release at glucose concentrations of 8 and 16 mM, but not at 3 mM (Fig. 4C) . (Collier et al., 2006) . The endogenous ligands for GPR40/FFA 1 , palmitic acid and oleic acid (Itoh et al., 2003) , were used as comparators. Before the experiment, we confirmed that TAK-875 (6.25-100 M), palmitic acid (62.5-1000 M), and oleic acid (62.5-1000 M) showed agonist activities in CHO cells expressing human or rat GPR40/FFA 1 in the presence of 1% BSA, corresponding to the BSA concentration to be used in the prolonged exposure experiments (Supplemental Fig. 1 ). In addition, we observed that palmitic acid, oleic acid, and TAK-875 dose-dependently augmented insulin secretion in INS-1 832/13 in the presence of 10 mM glucose and 1% BSA (Supplemental Fig. 2 ). These results indicate that TAK-875 sufficiently stimulates GPR40/FFA 1 within this dose range, compared with palmitic acid and oleic acid.
GPR40 Agonist as a Potential Antidiabetic
In INS-1 832/13 cells, 72-h exposure to palmitic acid (1000 M) together with 1% BSA resulted in a significant reduction in the insulin secretory response to 20 mM glucose (Fig. 5A) . Under the same conditions, neither oleic acid (10 -1000 M) nor TAK-875 (1-100 M) significantly altered glucose-stimulated insulin secretion in these cells. Intracellular insulin content was significantly reduced after 72-h exposure to palmitic acid (1000 M) or oleic acid (1000 M), and the deleterious effect was particularly pronounced for palmitic acid compared with oleic acid (p Յ 0.05 by Aspin-Welch test) (Fig. 5B) . In contrast, prolonged exposure to TAK-875 (100 M) did not affect intracellular insulin content.
Prolonged Agonist Stimulation of GPR40/FFA1 by TAK-875 Does Not Cause Induction of a Marker of Apoptosis in
Pancreatic ␤ Cells. It is well known that chronic exposure to FFAs in pancreatic ␤ cells causes not only impairment of their function but also cell apoptosis (Haber et al., 2003; Morgan, 2009) . To clarify the effects of prolonged exposure to TAK-875 on apoptotic events in ␤ cells, INS-1 832/13 cells were treated with TAK-875, palmitic acid, or oleic acid in the presence of 1% BSA for 72 h, and subsequent caspase 3/7 activity was measured. In these cells, 72-h exposure to palmitic acid (62.5-1000 M) and oleic acid (62.5-1000 M) caused dose-dependent enhancement of caspase 3/7 activity, and statistically significant effects were observed at doses above 250 M palmitic acid and 500 M oleic acid (Fig. 5, C and D) . In contrast, TAK-875 (6.25-100 M) did not show any effect on caspase 3/7 activity under the same conditions (Fig. 5E) .
TAK-875 Augments Insulin Secretion and Improves Glucose Tolerance during the Oral Glucose Tolerance
Test in Type 2 Diabetic Rats. Next, we performed an oral glucose tolerance test in type 2 diabetic N-STZ-1.5 rats (Portha et al., 1989) to examine the effects of TAK-875 on impaired postprandial glucose tolerance. Single oral administration of TAK-875 (1-10 mg/kg) to these rats 1 h before an oral glucose load resulted in a potent and dose-dependent reduction of glucose excursion (Fig. 6, A and B) . The effects on plasma glucose levels were probably mediated through the compound's effects on insulin, because plasma insulin levels, especially during the early phase of the oral glucose tolerance test, increased simultaneously and dose-dependently with TAK-875 (Fig. 6, C and D) .
Glucose-Lowering Effects of TAK-875 on Normal and Elevated Fasting Plasma Glucose. Because TAK-875 showed strictly glucose-dependent insulinotropic effects in vitro (Fig. 4) , we speculated that TAK-875 might enhance insulin secretion and reduce blood glucose only when blood glucose levels are elevated. To clarify the hypothesis, the effects of TAK-875 on fasting normoglycemia and hyperglycemia were examined in normal SD rats and ZDF rats, respectively. Two insulin secretagogues that act on the K ATP channel, nateglinide and the sulfonylurea glibenclamide, were included in these studies as comparators. As shown in Fig. 7 , A and B, nateglinide (50 mg/kg) lowered plasma glucose levels below normal fasting levels in SD rats by increasing plasma insulin. Likewise, glibenclamide (10 mg/kg) gradually decreased plasma glucose levels below normal fasting levels with a significant increase in plasma insulin levels. In contrast, TAK-875 at 30 mg/kg, which is a 3-to 10-fold higher dose compared with the dose that improved glucose tolerance in diabetic rats (Fig. 6) , did not alter fasting glucose levels in SD rats with normal glucose homeostasis (Fig. 7A) . Likewise, TAK-875 did not significantly alter insulin secretion in SD rats with normal fasting glucose levels (Fig. 7B) .
The effects of TAK-875, glibenclamide, and nateglinide on fasting hyperglycemia were evaluated in male ZDF rats. As shown in Fig. 7C , fasting plasma glucose levels before drug administration were significantly elevated in ZDF rats compared with the normal ZL rats. In ZDF rats, oral administration of TAK-875 (10 mg/kg) increased plasma insulin levels (Fig. 7D ) and lowered plasma glucose levels (Fig. 7C) , whereas nateglinide (50 mg/kg) and glibenclamide (10 mg/kg) did not show statistically significant change.
Discussion
GPR40/FFA 1 is highly expressed in pancreatic islets in mice, rats, and humans (Briscoe et al., 2003; Itoh et al., 2003; Tomita et al., 2006) . Although it has been reported that GPR40/FFA 1 is expressed not only in pancreatic ␤ cells (insulin-positive cells) but also in ␣ cells (glucagon-positive cells) in mice (Flodgren et al., 2007) , expression in insulin-positive cells is dominant in rats and humans (Itoh et al., 2003; Tomita et al., 2006) . In this study, we focused on the function of GPR40/FFA 1 in pancreatic ␤ cells and examined the events caused by pharmacological activation of the receptor by using in vitro and in vivo rat models. Our data indicate that TAK-875 is a potent agonist for GPR40/FFA 1 and activates the phospholipase C pathway, presumably via Gq␣ in pancreatic ␤ cells. This mechanism of insulinotropic action by TAK-875 is novel among insulinotropic drugs, including sulfonylureas, meglitinides, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) analogs, and is distinct from those of glucose-dependent insuli- (Drucker, 2007; Winzell and Ahrén, 2007) .
We found that TAK-875 enhanced [Ca 2ϩ ] i in a glucosedependent manner in INS-1 cells. Because the increase in [Ca 2ϩ ] i is related to enhanced insulin secretion in ␤ cells (Prentki et al., 1997) , this mechanism may explain the glucose-dependent insulinotropic effects of TAK-875 through GPR40/FFA 1 . The phenomenon was consistent with other reports in which enhancement of [Ca 2ϩ ] i in rat primary ␤ cells by stimulation of GPR40/FFA 1 with oleic acid depends on glucose concentration (Fujiwara et al., 2005) . A specific receptor for IP 3 is present in the endoplasmic reticulum (ER), and the interaction of IP 3 with the IP 3 receptor triggers calcium release from the ER (Berridge, 1993) . TAK-875 also enhanced intracellular IP production, thus, an increase in [Ca 2ϩ ] i with TAK-875 may, at least in part, result from calcium release from the ER. The interesting observation is that IP production by TAK-875 was not glucose-dependent, whereas enhancement of [Ca 2ϩ ] i and insulin release strictly depended on glucose concentration. Similar effects have been shown in Gq␣-coupled muscarinic receptors stimulated with the agonist carbachol, in which IP production occurs regardless of glucose concentration, whereas insulin release is glucose concentration-dependent in rat islets (Zawalich et al., 1989) . Thus, one explanation is that these events might be common phenomena among Gq␣-coupled receptors. Another explanation is that the difference may be caused by the different type of assay used: real-time and transient measurement of intracellular calcium versus measurement of cumulative IP, which is the degradation product of IP 3 . Further analysis will be necessary to clarify how GPR40/FFA 1 -mediated signals interact with glucose in pancreatic ␤ cells.
Postprandial and fasting hyperglycemia caused by insufficient insulin secretion in response to blood glucose is ob- served in patients with type 2 diabetes. Our results indicate that TAK-875 directly acts on pancreatic ␤ cells but augments insulin secretion only when blood glucose levels are elevated. Indeed, in vivo oral administration of TAK-875 (3-10 mg/kg) in type 2 diabetic rats improved both postprandial and fasting hyperglycemia. In terms of future studies, it will be of interest to determine whether chronic exposure to TAK-875 in vivo improves type 2 diabetes. Especially, male 
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at ASPET Journals on April 13, 2017 jpet.aspetjournals.org ZDF rats, in which the single oral dose of TAK-875 improved fasting hyperglycemia, exhibit severe type 2 diabetes with age-dependent decline of plasma insulin levels and ␤ cell mass (Pick et al., 1998) . Thus, future studies will focus on the effects of multiple doses of TAK-875 on pancreatic ␤ cell function, apoptosis, and islet morphology in this rat model. On the other hand, oral administration of high doses of TAK-875 (30 mg/kg) in normal fasted rats did not induce hypoglycemia. Oral administration of TAK-875 results in rapid absorption of the compound (T max ϭ 1 h) (Negoro et al., 2010) , indicating that the absence of hypoglycemic events and the minor insulinotropic effects observed in normal rats receiving high doses of TAK-875 may not be caused by the low plasma concentration of the compound. Rather, these results suggest that TAK-875 may present a low risk of hypoglycemia, an adverse effect common to sulfonylureas and meglitinides.
Although GPR40/FFA 1 has been considered a possible lipotoxicity mediator (Steneberg et al., 2005) , a number of experimental observations do not support a central role for GPR40/FFA 1 in lipotoxicity (Latour et al., 2007; Kebede et al., 2008; Lan et al., 2008; Alquier et al., 2009; Nagasumi et al., 2009 ). In our experiments, prolonged agonist stimulation to TAK-875 for 72 h in INS-1 cells, at the dose range in which sufficient agonist activity was observed, did not affect subsequent glucose-stimulated insulin secretion, insulin content, or caspase 3/7 activity, whereas FFAs did affect these parameters. In addition, we did not observe any correlation between these events and agonist activity for GPR40/FFA 1 . Our results, therefore, suggest that chronic toxic events induced by FFAs may be independent of GPR40/FFA 1 , and chronic activation of GPR40/FFA 1 by TAK-875 may not lead to either ␤ cell dysfunction or apoptosis. FFAs may induce toxicological effects by other mechanisms, such as long-chain fatty acylcoenzyme A accumulation, ceramide synthesis, and ER stress induction (Haber et al., 2003; Morgan, 2009) .
Currently, GLP-1 analogs and DPP-4 inhibitors are in clinical use. GLP-1 analogs are glucose-dependent insulinotropic agents, showing excellent efficacy for the treatment of diabetes with a low risk of hypoglycemia. However, these drugs are peptides and currently require administration via injection (Mikhail, 2008) . On the other hand, DPP-4 inhibitors are orally available small-molecule insulinotropic drugs, with an excellent safety profile. However, the indirect insulinotropic effects dependent on endogenous GLP-1 and/or glucose-dependent insulinotropic polypeptide may limit the efficacy in some patients.
Combination therapy with antidiabetic drugs is often used for the treatment of type 2 diabetes. Our results indicate that TAK-875 is a glucose-dependent insulinotropic agent with a low risk of hypoglycemia. These novel features may allow the use of TAK-875 in combination with insulin sensitizers (metformin and thiazolidines) and ␣-glucosidase inhibitors, with a reduced risk of hypoglycemic events. In addition, because TAK-875 has novel insulinotropic effects, the combination with insulin secretagogues such as sulfonylureas, DPP-4 inhibitors, and GLP-1 analogs may potentiate their glucoselowering effects.
In conclusion, our results indicate that the GPR40/FFA 1 agonist TAK-875 has the potential to be a highly effective drug that warrants further investigation for the treatment of type 2 diabetes.
